Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
02 juil. 2024 08h00 HE
|
Annovis Bio, Inc.
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a...
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
27 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
26 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
25 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Clearday Supports National Health Observances
12 juin 2024 16h00 HE
|
Clearday, Inc.
San Antonio, TX, June 12, 2024 (GLOBE NEWSWIRE) -- Clearday (OTC- CLRD), supports the post on May 29, 2024, from the Office of Disease Prevention and Health Promotion. Said office features monthly...
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
11 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for...
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
05 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
12 mars 2024 15h10 HE
|
Spherix Global Insights
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming...
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
11 mars 2024 07h00 HE
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
22 févr. 2024 15h04 HE
|
Spherix Global Insights
EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation...